Yu K, Shin Y, Kim D, Kim J, Kang J, Singh P
Virol J. 2025; 22(1):65.
PMID: 40055750
PMC: 11887385.
DOI: 10.1186/s12985-025-02680-3.
Fesatidou M, Petrou A, Geronikaki A
Chem Biodivers. 2024; 21(12):e202401697.
PMID: 39442074
PMC: 11644116.
DOI: 10.1002/cbdv.202401697.
Kannan S, Gillespie S, Picking W, Picking W, Lorson C, Singh K
Biology (Basel). 2024; 13(4).
PMID: 38666816
PMC: 11048162.
DOI: 10.3390/biology13040204.
Wang Z, Zhang H, Gao Z, Sang Z, De Clercq E, Pannecouque C
Acta Pharm Sin B. 2024; 14(3):1257-1282.
PMID: 38486991
PMC: 10935503.
DOI: 10.1016/j.apsb.2023.11.023.
Khuttan S, Gallicchio E
J Chem Theory Comput. 2024; 20(3):1489-1501.
PMID: 38252868
PMC: 10867849.
DOI: 10.1021/acs.jctc.3c01250.
Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use.
Maruapula D, Moraka N, Bareng O, Mokgethi P, Choga W, Seatla K
J Antimicrob Chemother. 2023; 78(10):2489-2495.
PMID: 37585352
PMC: 10545497.
DOI: 10.1093/jac/dkad258.
Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
Jiang X, Huang B, Rumrill S, Pople D, Zalloum W, Kang D
Commun Chem. 2023; 6(1):83.
PMID: 37120482
PMC: 10148624.
DOI: 10.1038/s42004-023-00888-4.
Covalently Targeted Highly Conserved Tyr318 to Improve the Drug Resistance Profiles of HIV-1 NNRTIs: A Proof-of-Concept Study.
Zhou Z, Meng B, An J, Zhao F, Sun Y, Zeng D
Int J Mol Sci. 2023; 24(2).
PMID: 36674730
PMC: 9865928.
DOI: 10.3390/ijms24021215.
Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties.
Prener L, Baszczynski O, Kaiser M, Dracinsky M, Stepan G, Lee Y
J Med Chem. 2023; 66(3):1761-1777.
PMID: 36652602
PMC: 10017027.
DOI: 10.1021/acs.jmedchem.2c01574.
Identification of Novel Diarylpyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors by Exploring the Primer Grip Region.
Zhang T, Zhou Z, Zhao F, Sang Z, De Clercq E, Pannecouque C
Pharmaceuticals (Basel). 2022; 15(11).
PMID: 36422568
PMC: 9697031.
DOI: 10.3390/ph15111438.
Implications of Fragment-Based Drug Discovery in Tuberculosis and HIV.
Mallakuntla M, Togre N, Santos D, Tiwari S
Pharmaceuticals (Basel). 2022; 15(11).
PMID: 36422545
PMC: 9692459.
DOI: 10.3390/ph15111415.
APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants.
Dwivedi R, Wang Y, Kline C, Fischer D, Ambrose Z
Front Virol. 2022; 2.
PMID: 35957953
PMC: 9364801.
DOI: 10.3389/fviro.2022.919825.
studies of diarylpyridine derivatives as novel HIV-1 NNRTIs using docking-based 3D-QSAR, molecular dynamics, and pharmacophore modeling approaches.
Wan Y, Tian Y, Wang W, Gu S, Ju X, Liu G
RSC Adv. 2022; 8(71):40529-40543.
PMID: 35557880
PMC: 9091378.
DOI: 10.1039/c8ra06475j.
Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2.
Lee R, Li T, Chang S, Chao T, Kuo C, Pan M
Int J Mol Sci. 2022; 23(7).
PMID: 35409412
PMC: 8999638.
DOI: 10.3390/ijms23074050.
Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase.
Frey K, Bertoletti N, Chan A, Ippolito J, Bollini M, Spasov K
Front Mol Biosci. 2022; 9:805187.
PMID: 35237658
PMC: 8882919.
DOI: 10.3389/fmolb.2022.805187.
An Overview of Human Immunodeficiency Virus-1 Antiretroviral Drugs: General Principles and Current Status.
Shin Y, Park C, Yoon C
Infect Chemother. 2021; 53(1):29-45.
PMID: 34409780
PMC: 8032919.
DOI: 10.3947/ic.2020.0100.
Small Molecules of Natural Origin as Potential Anti-HIV Agents: A Computational Approach.
Crisan L, Bora A
Life (Basel). 2021; 11(7).
PMID: 34357094
PMC: 8303883.
DOI: 10.3390/life11070722.
The development of an effective synthetic route of rilpivirine.
Zhang T, Yang J, Zhou Z, Fu Z, Cherukupalli S, Kang D
BMC Chem. 2021; 15(1):22.
PMID: 33810807
PMC: 8017658.
DOI: 10.1186/s13065-021-00749-y.
Alkylated benzimidazoles: Design, synthesis, docking, DFT analysis, ADMET property, molecular dynamics and activity against HIV and YFV.
Srivastava R, Gupta S, Naaz F, Sen Gupta P, Yadav M, Singh V
Comput Biol Chem. 2020; 89:107400.
PMID: 33068917
PMC: 7537607.
DOI: 10.1016/j.compbiolchem.2020.107400.
Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV.
Himmel D, Arnold E
Pharmaceuticals (Basel). 2020; 13(6).
PMID: 32545407
PMC: 7345359.
DOI: 10.3390/ph13060122.